Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03988114
Title A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (proMONARCH)
Recruitment Withdrawn
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer


Abemaciclib + Anastrozole

Abemaciclib + Letrozole

Age Groups: adult | senior
Covered Countries USA | ITA | DEU | BEL | AUT

No variant requirements are available.